Martin Kolev

Join this workshop to deepen your understanding of the complement-mediated combination therapies to work towards expansion beyond rare diseases.

• Discussing the precise molecular mechanisms where specific complement components drive immunosuppression within the tumour, exploring the signalling pathways involved
• Exploring the preclinical and emerging clinical data supporting the links between the complement and immune checkpoint pathways, focusing on how these combinations enhance anti-tumour effector functions in otherwise resistant tumours
• Examine the use of combining inhibitors targeting distinct, pathogenic complement pathways in complex autoimmune diseases to overcome single-pathway mechanisms
• Analyzing biomarker strategies and diagnostic approaches required to identify specific patient subsets in both oncology and autoimmunity that are most likely to benefit from defined complement combination regimens
• Exploring the rationale for applying complement combination strategies to a broader spectrum of multifactorial diseases where complement contributes to, but may not be the sole driver of, pathology
• Delving into the development and application of delivery technologies that enable effective sequential delivery of multiple complement-modulating therapies
• Assessing the complex PK/PD interactions and potential for synergy when combining different complement inhibitors or combining them with non-complement drugs, to determine optimal dosing
• Advancing complement combination therapies, including the identification of novel intracellular complement targets and the development of bispecific or multi-specific therapies